Page 11 - Test PDF v5

« Back to Contents OVARIAN CANCER

LiFE re

Literature for ENYGO

Medical treatment of recurrent ovarian cancer

Editor Kamil Zalewski, Kristina Lindemann, Michael J. Halaska

Descriptive summary Pujade-Lauraine et al. published the results of a phase II trial evalu-
ating volasertib (selective cell-cycle kinase inhibitor) or single-agent
In view of the common use of carboplatin plus pegylated liposomal dox- chemotherapy in patients with platinum-resistant or refractory OC [4].
orubicin (PLD) in patients with platinum-sensitive OC and the encourag- Volasertib (selective cell-cycle kinase inhibitor) resulted in manageable
ing results of studies with farletuzumab (a monoclonal antibody against adverse effects, which were mostly haematologic [4]. The median PFS
folate receptor alpha, FAB), a phase Ib study of FAR plus carboplatin and for volasertib was 13.1 weeks and 20.6 weeks for the investigator’s
PLD was undertaken for the treatment of platinum-sensitive OC in first or choice single-agent, nonplatinum, cytotoxic chemotherapy. In the
second relapse [1]. The aim of the study was to assess the safety of this volasertib arm, 11 % of patients achieved PFS greater than or equal to 1
triple-agent combination in this disease context. Farletuzumab did not year, in contrast to no patients in the chemotherapy arm.
add substantial toxicity to the chemotherapy backbone.

Bell-McGuinn et al. failed to show iniparib (4-iodo-3-nitrobenzamide)
monotherapy to be effective in patients with recurrent BRCA1- or
BRCA2-associated OC [2]. None of the 12 patients responded.

Emons et al. reported a phase II study with platinum-refractory/resistant
OC or advanced/recurrent endometrial cancer (EC) patients treated with
mTOR inhibitor temsirolimus. Although toxicity was acceptable and
durable disease stabilisation was observed in some patients, the low
efficacy (progressive disease at 8 weeks in 10/21 and 8/20 patients with
OC and EC, respectively) led to premature closure of the trial [3].

Relevant articles retrieved Nov 2015 - Feb 2016

No Title Authors Journal Link to abstract

1 Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal Kim KH et al. Gynecol Oncol. http://www.ncbi.nlm.nih.gov/
doxorubicin in patients with platinum-sensitive epithelial ovarian cancer. pubmed/26644263
http://www.ncbi.nlm.nih.gov/
2 A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Bell-McGuinn KM et al. Int J Gynecol Cancer. pubmed/26745694
Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritone-
al Cancer. http://www.ncbi.nlm.nih.gov/
pubmed/26731724
3 Temsirolimus in women with platinum-refractory/resistant ovarian cancer or Emons G et al. Gynecol Oncol.
advanced/recurrent endometrial carcinoma. A phase II study. of the AGO-stu- http://www.ncbi.nlm.nih.gov/
dy group (AGO-GYN8). pubmed/26755507

4 Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Pujade-Lauraine E et al. J Clin Oncol.
Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour
l'Etude des Cancers de l'Ovaire Study.

Continued on the next page  Page 11

International Journal of Gynecological Cancer, Volume 26, Supplement #1